<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2340">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787211</url>
  </required_header>
  <id_info>
    <org_study_id>BRII-196-198-004</org_study_id>
    <nct_id>NCT04787211</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brii Biosciences Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TSB Therapeutics (Beijing) CO.LTD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brii Biosciences Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this phase 2 study is to evaluate the safety and efficacy of single dose IV&#xD;
      infusion of BRII-196 and BRII-198 given as combination therapy in patients with severe&#xD;
      COVID-19, and mild to moderate COVID-19 and asymptomatic carrier.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to Day 181</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to Day 181</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-dose baseline in RBC count</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-dose baseline in WBC count</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-dose baseline in Platelets count</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-dose baseline in Hemoglobin result</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-dose baseline in Creatine kinase result</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-dose baseline in Alanine aminotransferase (ALT) result</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-weighted average changes in SARSCoV-2 RNA levels in nasopharyngeal swabs from baseline to Day 8</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of COVID-19 related symptoms through Day 29 among subjects with mild-moderate COVID-19</measure>
    <time_frame>up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have mild-moderate COVID-19 and develop severe COVID-19 after randomization</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameters (Group A and B): maximum serum concentration observed (Cmax)</measure>
    <time_frame>up to Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>BRII-196 and BRII-198 in adult subjects with severe COVID-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in adult subjects with mild-moderate COVID-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BRII-196 and BRII-198</intervention_name>
    <description>BRII-196 and BRII-198 given by intravenous administration</description>
    <arm_group_label>BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19</arm_group_label>
    <arm_group_label>BRII-196 and BRII-198 in adult subjects with severe COVID-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given by intravenous administration</description>
    <arm_group_label>Placebo in adult subjects with mild-moderate COVID-19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject ≥ 18 years, signing the informed consent.&#xD;
&#xD;
          -  SARS-CoV-2 infection by PCR ≤ 7 days&#xD;
&#xD;
          -  One or more of COVID-19 related symptoms or measured fever present within 48 hours&#xD;
             prior to study entry (subjects with mild-moderate COVID-19)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recurring COVID-19 patients&#xD;
&#xD;
          -  Subjects with any unstable conditions, a history of significant hypersensitivity, or&#xD;
             known allergy to components of the investigational agent&#xD;
&#xD;
          -  Receipt of convalescent COVID-19 plasma, SARS-CoV-2 mAb treatment, SARS-CoV-2 vaccine,&#xD;
             or other investigational treatments prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yao Zhang, MD</last_name>
    <role>Study Director</role>
    <affiliation>TSB Therapeutics (Beijing) CO.LTD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lili Chen</last_name>
    <phone>+86 10 6299 8808</phone>
    <email>lili.chen@briibio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site 1</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <email>ctcentre@hku.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 phase 2</keyword>
  <keyword>monoclonal antibody</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

